Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease

Vedolizumab is used as a treatment for patients with inflammatory bowel disease (IBD), but induction therapy leads to clinical response and remission in approximately 55% and 30% of patients with IBD, respectively. In this study, we aimed to explore the predictive value of mucosal eosinophils and se...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabriëls, Ruben Y., Bourgonje, Arno R., von Martels, Julius Z. H., Blokzijl, Tjasso, Weersma, Rinse K., Galinsky, Kevin, Juarez, Julius, Faber, Klaas Nico, Kats-Ugurlu, Gursah, Dijkstra, Gerard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318498/
https://www.ncbi.nlm.nih.gov/pubmed/35887905
http://dx.doi.org/10.3390/jcm11144141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318498/
https://www.ncbi.nlm.nih.gov/pubmed/35887905
http://dx.doi.org/10.3390/jcm11144141

Ejemplares similares